Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock

Core Viewpoint - Calidi Biotherapeutics Inc. has successfully closed a public offering of 4,437,869 shares at $1.69 per share, raising approximately $7.5 million in gross proceeds [1]. Group 1: Public Offering Details - The public offering was conducted under registration statements on Form S-3, which were declared effective by the SEC on October 10, 2024 [2]. - The final prospectus related to the offering was filed with the SEC on November 15, 2024, and is accessible on the SEC's website [2]. Group 2: Company Overview - Calidi Biotherapeutics is a clinical-stage immuno-oncology company focused on developing targeted antitumor virotherapies using proprietary technology [3]. - The company utilizes allogeneic stem cells to deliver oncolytic viruses for treating various oncology indications, including high-grade gliomas and solid tumors [3]. - Calidi's platforms aim to enhance the efficacy and safety of oncolytic viruses, potentially treating or preventing metastatic disease [3].